Drugs Made In America Acquisition II Corp. Unit (DMIIU) Research

DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing. Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.

Market snapshot

Symbol
DMIIU
Price
$10.14
Day change
+0.20%
Market cap
$705.2M
52-week range
9.935-10.8
Sector
Financial Services
Industry
Asset Management

Peer companies

  • Eagle Point Income Company Inc. (EIC)
  • Gladstone Investment Corporation (GAIN)
  • General American Investors Company, Inc. (GAM)
  • MSC Income Fund, Inc. (MSIF)
  • Nuveen Churchill Direct Lending Corp. (NCDL)
  • NewtekOne, Inc. (NEWT)
  • OFS Credit Company, Inc. (OCCI)

Open Drugs Made In America Acquisition II Corp. Unit (DMIIU) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.